CLEVELAND, Feburary 9, 2026 — Leads & Copy —
Abeona Therapeutics Inc. (Nasdaq: ABEO) has granted equity awards to new non-executive employees, the company announced today. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards on January 31, 2026, as a material inducement to employment for seven individuals. These equity awards relate to an aggregate of up to 28,676 restricted shares of Abeona common stock.
One-third of the shares subject to the restricted stock awards will vest yearly on each anniversary of the grant date. The shares granted to each employee will be fully vested on the third anniversary of the grant date, contingent upon the employee’s continued employment with Abeona on the applicable vesting dates.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases. Its product, ZEVASKYN® (prademagene zamikeracel), is an autologous cell-based gene therapy for treating wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Abeona’s cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The company’s development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s next-generation AAV capsids are being evaluated for various diseases.
ZEVASKYN®, Abeona Assist®, and Abeona Therapeutics® are trademarks of Abeona Therapeutics Inc.
Source: Abeona Therapeutics Inc.
